Modality
Vaccine
MOA
Anti-Tau
Target
IL-17A
Pathway
Proteasome
MSADHD
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
~Dec 2017
→ ~Mar 2019
Phase 2
Jun 2019
→ Nov 2025
Phase 2Current
NCT03381197
2,945 pts·ADHD
2024-02→TBD·Terminated
NCT03662801
219 pts·ADHD
2019-06→2025-11·Recruiting
3,164 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-065mo agoPh2 Data· ADHD
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2
Recruit…
P2
Termina…
Catalysts
Ph2 Data
2025-11-06 · 5mo ago
ADHD
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03381197 | Phase 2 | ADHD | Terminated | 2945 | UPCR |
| NCT03662801 | Phase 2 | ADHD | Recruiting | 219 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A |